1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. CSL Limited
  6. News
  7. Press Releases
    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
Delayed Australian Stock Exchange  -  05/25 10:09:07 pm EDT
271.35 AUD   -0.82%
05/23Australian shares subdued as tech, healthcare offset mining gains
RE
05/11Australia shares slide as U.S. inflation data fuels slowdown woes
RE
05/11Australian shares rise on healthcare, mining boost; U.S. inflation data in focus
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société CSL LIMITED
03/29CSL Behring - European Medicines Agency Commences Review of Novel Gene Therapy Candidat..
AQ
03/28Seqirus Receives Health Canada Approval for Expanded Age Indication of Its Cell-Based Q..
AQ
03/23CSL BEHRING AG - PUBLICATION OF PROV : Participation rate of 94 percent
AQ
03/08PUBLICATION OF DEFINITIVE INTERIM RE : CSL Behring AG declares offer successful
BU
03/07Seqirus - Update on CDC Advisory Committee on Immunization Practices (ACIP) Review of E..
AQ
03/06CSL : Notification regarding unquoted securities - CSL
PU
03/03CSL : Notification regarding unquoted securities - CSL
PU
03/03Vifor Pharma Group - Publication of provisional interim result for Vifor Pharma tender ..
AQ
03/03Forbes Magazine Ranks Global Biotech Leader CSL Among America's Best Employers for 2022
AQ
02/23CSL : Change of Director's Interest Notice
PU
02/23CSL : Notification regarding unquoted securities - CSL
PU
02/15CSL : Half Year Results Investor Presentation
PU
02/15CSL : Half Year Results Announcement
PU
02/15CSL : Statutory Accounts for Half Year Ended 31 December 2021
PU
02/13CSL : Application for quotation of securities - CSL
PU
02/07CSL Behring - Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained..
AQ
01/06CSL : Notification regarding unquoted securities - CSL
PU
2021Global biotherapeutics - CSL Behring Receives Accelerated CHMP Assessment for Etranacog..
AQ
2021CSL : Investor Presentation CSL Swiss Tender Acquisition of Vifor
PU
2021CSL : Proposed issue of securities - CSL
PU
2021CSL : Swiss tender offer to acquire 100% of vifor pharma ltd
PU
2021CSL : Committed to mRNA Program
PU
2021CSL : Statement on Modern Slavery 2021
PU
2021CSL : Tax Transparency Report 2021
PU
2021CSL : Joins StartX Community
PU
2021CSL : Clinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines and N..
AQ
2021CSL : The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based ..
AQ
2021CSL : Seqirus Awarded U.S. Government Contract to Develop Two Pandemic Influenza Vaccines
AQ
2021CSL : Launches Annual Scholarship Program with Seven Greater Chicago Area Students Receivi..
AQ
2021CSL : Positive COVID-19 Case at Broadmeadows
PU
2021CSL : Annual Report
PU
2021CSL : Uncertainty Prevails For CSL
AQ
2021CSL : Results Announcement
PU
2021CSL : Dividend/Distribution - CSL
PU
2021CSL : Results Presentation
PU
2021CSL : Statutory Accounts for the Full Year Ended 30 June 2021
PU
2021CSL : The European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Forc..
AQ
2021CSL : Hizentra (Immune Globulin Subcutaneous 20% Liquid) To Be Covered Under Medicare Part..
AQ
2021CSL : Applications Open for Fellowships
PU
2021CSL : California Adds New Residential Remodeling Contractor License Classification, Effect..
AQ
2021CSL : welcomes the Patent Box Policy
PU
2021CSL : welcomes domestic mRNA vaccine development
PU
2021UNIQURE N : CSL Behring Announces Closing of Global Commercialization and License Agreemen..
AQ
2021CSL : Behring Announces Agreement with uniQure
PU
2021CSL : Update on COVID-19 Vaccine Numbers
PU
2021CSL : 2020 RAI Awardees Announced
PU
2021CALIFORNIA CONTRACTORS : New CSLB Procedure Requires Non-California Corporations To Associ..
AQ
2021CSL : update on ATAGI advice for AZ COVID-19 Vaccine
PU
2021CSL : Global Role in Battling COVID-19
AQ
2021CSL : Global Role in Battling COVID-19
PU
2021CSL : COVID-19 Update
PU
2021CSL : Dispatches COVID 19 Vaccine
PU
2021CSL : Seqirus Ready to Reinforce Canada's Influenza Pandemic Preparedness Plans
AQ
2021CSL : Seqirus Announces Health Canada Approval of Expanded Age Indication of Its Cell-Base..
AQ
2021CSL : Is CSL Ready To Turn Around?
AQ
2021CSL : COVID-19 Update
PU
2021CSL : Local Manufacturing of COVID-19 Vaccine Update
PU
2021CSL : Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engage..
AQ
2020CSL : COVID-19 Update
PU
2020CSL : Update on the UQ COVID-19 vaccine
PU
2020CSL : Global Role in Battling COVID-19
PU
2020CSL : COVID-19 Update
PU
2020CSL : Update on UQ-CSL v451 COVID-19 Vaccine
PU
2020CSL : Urban League, CSL Behring Partner to Address Community Needs including Public Health..
AQ
2020CSL : New Vaccine Manufacturing Facility
PU
2020CSL : Behring to Present New Real-World Data on Outcomes Following Acute Coronary Syndrome..
AQ
2020CSL : Appendix 2A
PU
2020CSL : University of Oxford/AstraZeneca Vaccine Candidate
PU
2020CSL : Named as one of the World's Best Employers
AQ
2020CSL : Broad Response to COVID-19 and Advancements across the Company's Strategic Scientifi..
AQ
2020CSL : Annual Research and Development Day Briefing
PU
2020CSL : Agreement to supply 51 mil vaccine doses
PU
2020CSL : Notice of Research & Development Investor Briefing
PU
2020CSL : Appendix 3G
PU
2020CSL : Change of Director's Interest Notice
PU
1  2  3  4Next
Upcoming event on CSL LIMITED